Some believe that effective communication between doctor and patient is a core clinical skill that should be taught as rigorously as other medical sciences are taught. Underlying this belief is a growing body of research and development of guidelines acknowledging that physicians need not be born with excellent communication skills but can learn as they practice various other aspects of medicine.
Clinicians specializing in cancer acknowledge that insufficient training...
Added text to state that the choice of anthracycline and the anthracycline dose-intensity may influence the survival of patients with acute myeloid leukemia (AML).
Added text to state that in patients aged 60 years and younger, outcomes for those receiving daunorubicin were superior to those receiving more traditional dosing; complete remission rate was 71% versus 57%, and median survival was 24 months versus 16 months (cited Fernandez et al. as reference 7); however, no comparison data for daunorubicin administered at different dosing rates are available.Two studies examined when idarubicin versus daunorubicin were administered to elderly patients and found that overall survival was not impacted by the choice of anthracycline, but the percentage of long-term disease-free survivors in a mixed-cure model did appear to be impacted (cited Gardin et al. as reference 8). The addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline in patients aged 51 to 79 years led to a small increase in median survival (cited 2012 Burnett et al. as reference 9). In contrast, gemtuzumab did not improve the 1-year survival rate of elderly patients receiving low-dose cytarabine, although the CR rate increased from 17% to 30% (cited 2013 Burnett et al. as reference 10).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
In this article
This information is produced and provided by the National
Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National
Institute via the Internet web site at http://
.gov or call 1-800-4-CANCER.
WebMD Public Information from the National Cancer Institute
September 04, 2014
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this